A Phase 2 interventional study of Rituximab in Severe Aplastic Anemia and Platelet Transfusion Refractoriness, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-12.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China — 16 open to participants now, 18 under way, none of them phase 3. Anemia, Aplastic · Institute of Hematology & Blood Diseases Hospital, China.
Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, this one is the 18th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2023, is one of 14 in phase 2, reaches primary completion later than 4 of the 17 other live ones, and was the 14th registered.
373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.
Browse Anemia, Aplastic studies →16 of the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–40
By country, each count listing its studies:
Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 17
First in 2012; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 40 across the 25 interventional studies, 462 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.
3 of the studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06254560Institute of Hematology & Blood Diseases Hospital, ChinaRituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness | 2026-12-30 |
| NCT07297550Institute of Hematology & Blood Diseases Hospital, ChinaSafety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia | 2026-12-31 |
| NCT06936930Institute of Hematology & Blood Diseases Hospital, ChinaReproductive and Mental Health of Patients With Aplastic Anemia | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR). Unlike immune thrombocytopenia (ITP), glucocorticoids and human immunoglobulin (IVIg) are generally ineffective for PTR. Due to the lack of effective intervention methods, patients with PTR suffer increased platelet transfusions, bleeding events and treatment costs, prolonged hospital stays, and decreased survival rate. SAA with PTR has become a challenge for physicians. The experiment aims to explore the efficacy of rituximab in the treatment of SAA with PTR, and establish a new effective, safe treatment method with relatively low treatment cost.
During the treatment period, Rituximab is administered at a dose of 100mg per week, a total of 4 times.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rituximab combined with cyclosporine
Drug: Rituximab
Rituximab is administered at a dose of 100mg per week, a total of 4 times. Cyclosporin is administered at a dose of 3-5mg/kg per day.
Also known as: Mabthera
The response and complete remission rate with Rituximab protocol.
Response will be evaluated at each clinic visit. Complete response (CR) was defined as achieving all three peripheral blood count criteria: (1) Hb level up to the normal range; (2) ANC≥1.5×109/L; (3) PLT≥100×109/L. Partial response (PR) was defined as transfusion independent, no longer meeting criteria for severe disease. Persistence of transfusion requirement or death was evidence of no response (NR).
Time frame: 6 months
Relapse rate
Relapse was defined as a responder who met criteria for SAA again after achieving response and keeping stable blood counts for at least 3 months.
Time frame: 12 months and 60 months
Sustained response (SR)
SR was defined as Hb \> 10 g/dL at 12 months and 60 months, in the absence of any treatment.
Time frame: 12 months and 60 months
Survival
Survival rate within 5 years after diagnosis
Time frame: 60 months
Clonal evolution to myelodysplasia and acute leukemia.
Clonal evolution within 5 years after diagnosis
Time frame: 60 months
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.
Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 46 months is below that.
Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Institute of Hematology & Blood Diseases Hospital, China →